v3.26.1
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Operating Activities:    
Net loss $ (10,168) $ (12,827)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization [note 3] 57 62
Stock-based compensation [note 7[c], note 7[e] and note 7[f]] (685) 2,232
Amortization of 2024 SVB convertible term loan transaction costs [note 6] 12 14
Change in fair value of contingent consideration [note 4 and note 5] (285) 91
Changes in operating assets and liabilities:    
Accrued compensation 261 (2,064)
Lease obligation [note 9]   1
Net cash used in operating activities (6,932) (11,088)
Financing Activities:    
Proceeds from exercise of warrants 21  
Net cash provided by financing activities 21  
Investing Activities:    
Purchase of marketable securities (1,156) (3,363)
Maturities of marketable securities 15,432 14,716
Net cash provided by (used in) investing activities 14,276 11,353
Effect of exchange rate changes on cash   (2)
Net increase (decrease) in cash, cash equivalents and restricted cash 7,364 263
Cash, cash equivalents and restricted cash at beginning of the period 20,949 12,773
Cash, cash equivalents and restricted cash at end of the period 28,313 13,036
Nonrelated Party [Member]    
Changes in operating assets and liabilities:    
Prepaid expenses and other assets 1,625 85
Accounts payable (53) (293)
Accrued liabilities, other 1,735 732
Accrued clinical liabilities 267 $ 879
Related Parties [Member]    
Changes in operating assets and liabilities:    
Prepaid expenses and other assets 68  
Accounts payable 19  
Accrued liabilities, other (1)  
Accrued clinical liabilities $ 216